DDInter22 DDInter1180
Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012.
Methscopolamine is a quaternary ammonium derivative of scopolamine and antagonist at muscarininc (mACh) receptors. Methscopolamine bromide is the most common form of the active ingredient in oral pharmaceutical products. The oral tablets are used as an adjunct therapy for the treatment of peptic ulcer and is shown to be effective in decreasing the rate of recurrence of peptic ulcers as well as preventing complications.
Aclidinium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trospium
Aclidinium {u} (Compound) binds {v} (Gene) CHRM2
Aclidinium {u} (Compound) is included by {v} (Pharmacologic Class) Cholinergic Antagonists
Aclidinium {u} (Compound) causes {v} (Side Effect) Bladder neck obstruction
Aclidinium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Umeclidinium
Aclidinium {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tiotropium
Aclidinium may cause a moderate interaction that could exacerbate diseases when taken with Trospium
Aclidinium (Compound) binds CHRM2 (Gene)
Aclidinium (Compound) is included by Cholinergic Antagonists (Pharmacologic Class)
Aclidinium (Compound) causes Bladder neck obstruction (Side Effect)
Aclidinium may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Aclidinium (Compound) resembles Tiotropium (Compound) and Aclidinium may cause a moderate interaction that could exacerbate diseases when taken with Tiotropium